News J&J gets restricted label for PARP drug Akeega in EU Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
